TVTX

SEC source: 0001680739-26-000005 · form4-04162026_040405.xml · nonDerivative · entry 6

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,250

F1 · kind: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person.

SEC source: 0001680739-26-000005 · form4-04162026_040405.xml · nonDerivative · entry 5

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001680739-26-000005 · form4-04162026_040405.xml · nonDerivative · entry 4

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001680739-26-000005 · form4-04162026_040405.xml · nonDerivative · entry 3

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 59,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001680739-26-000005 · form4-04162026_040405.xml · nonDerivative · entry 2

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 54,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001680739-26-000005 · form4-04162026_040405.xml · nonDerivative · entry 1

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001902368-26-000005 · form4-04162026_010435.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,706

F1 · kind: On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.

SEC source: 0001698262-26-000002 · form4-04162026_010440.xml · nonDerivative · entry 1

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 123,087

F1 · kind: On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.

SEC source: 0001789617-26-000002 · form4-04162026_010423.xml · nonDerivative · entry 1

Heerma Peter · CIK 0001789617 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,823

F1 · kind: On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.

SEC source: 0001763494-26-000005 · form4-04162026_010408.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 496,886

F1 · kind: On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.

SEC source: 0001283303-26-000008 · form4-04162026_010431.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 119,211

F1 · kind: On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.

SEC source: 0001943192-26-000003 · form4-04162026_010454.xml · nonDerivative · entry 2

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,161

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001943192-26-000003 · form4-04162026_010454.xml · nonDerivative · entry 1

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,226

F1 · kind: On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.

SEC source: 0001680739-26-000003 · form4-04072026_100418.xml · derivative · entry 3

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2028-05-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001680739-26-000003 · form4-04072026_100418.xml · nonDerivative · entry 2

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 37,500

F1 · kind: This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on May 9, 2018.

SEC source: 0001680739-26-000003 · form4-04072026_100418.xml · nonDerivative · entry 1

Baynes Roy D. · CIK 0001680739 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001763494-26-000004 · form4-04022026_050410.xml · derivative · entry 4

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 60,000 shares

Expires 2030-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001763494-26-000004 · form4-04022026_050410.xml · nonDerivative · entry 3

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 432,886

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020.

F3 · price: The weighted average sale price for the transaction reported was $31.46, and the range of prices were between $31.15 and $31.67. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001763494-26-000004 · form4-04022026_050410.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 457,984

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020.

F2 · price: The weighted average sale price for the transaction reported was $30.55, and the range of prices were between $30.13 and $31.07. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001763494-26-000004 · form4-04022026_050410.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 492,886

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001283303-26-000007 · form4-04022026_050408.xml · derivative · entry 3

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 10,000 shares

Expires 2030-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001283303-26-000007 · form4-04022026_050408.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,211

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 31, 2020.

SEC source: 0001283303-26-000007 · form4-04022026_050408.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,211

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001283303-26-000006 · form4-03182026_040301.xml · derivative · entry 3

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2027-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001283303-26-000006 · form4-03182026_040301.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,211

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027.

F2 · price: The weighted average sale price for the transaction reported was $28.0861, and the range of prices were between $27.66 and $28.40. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001283303-26-000006 · form4-03182026_040301.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,211

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001763494-26-000003 · form4-02242026_040201.xml · derivative · entry 3

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2030-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001763494-26-000003 · form4-02242026_040201.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 432,886

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended.

F2 · price: The weighted average sale price for the transaction reported was $30.0961, and the range of prices were between $30.00 and $30.325. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001763494-26-000003 · form4-02242026_040201.xml · nonDerivative · entry 1

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 492,886

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001283303-26-000005 · form4-02192026_040201.xml · derivative · entry 4

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 10,000 shares

Expires 2027-01-04

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option is fully vested and exercisable.

SEC source: 0001283303-26-000005 · form4-02192026_040201.xml · nonDerivative · entry 3

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,211

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027.

F3 · price: The weighted average sale price for the transaction reported was $28.262, and the range of prices were between $28.09 and $28.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001283303-26-000005 · form4-02192026_040201.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,532

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying a stock option grant to the Reporting Person on January 4, 2017 with an expiration date of January 4, 2027.

F2 · price: The weighted average sale price for the transaction reported was $27.504, and the range of prices were between $27.01 and $27.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001283303-26-000005 · form4-02192026_040201.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 115,211

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001902368-26-000004 · form4-02052026_040203.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,706

F1 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3 · price: The weighted average sale price for the transaction reported was $32.85, and the range of prices were between $32.80 and $32.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001902368-26-000004 · form4-02052026_040203.xml · nonDerivative · entry 1

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,938

F1 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $32.11, and the range of prices were between $31.65 and $32.61. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001943192-26-000002 · form4-02052026_040201.xml · nonDerivative · entry 2

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,226

F1 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001943192-26-000002 · form4-02052026_040201.xml · nonDerivative · entry 1

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,336

F1 · kind: This sale was made pursuant to a written plan adopted on May 28, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $32.14, and the range of prices were between $31.645 and $32.645. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001283303-26-000003 · form4-02052026_040205.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,211

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3 · price: The weighted average sale price for the transaction reported was $32.74, and the range of prices were between $32.64 and $32.90. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

SEC source: 0001283303-26-000003 · form4-02052026_040205.xml · nonDerivative · entry 1

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 105,720

F1 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F2 · price: The weighted average sale price for the transaction reported was $32.07, and the range of prices were between $31.63 and $32.61. Upon request by the SEC staff, the Issuer, or any security holder of theIssuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001882909-26-000001 · form4-02032026_090201.xml · nonDerivative · entry 2

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,080

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001902368-26-000003 · form4-02032026_090210.xml · nonDerivative · entry 2

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,485

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001763494-26-000002 · form4-02032026_090212.xml · nonDerivative · entry 3

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 432,886

F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F4 · price: The weighted average sale price for the transaction reported was $32.70, and the range of prices were between $32.5248 and $32.88. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001763494-26-000002 · form4-02032026_090212.xml · nonDerivative · entry 2

Dube Eric M · CIK 0001763494 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 466,521

F2 · kind: This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

F3 · price: The weighted average sale price for the transaction reported was $32.06, and the range of prices were between $31.52 and $32.52. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.

SEC source: 0001943192-26-000001 · form4-02032026_090208.xml · nonDerivative · entry 2

Cline Christopher R. · CIK 0001943192 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,971

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001789617-26-000001 · form4-02032026_090207.xml · nonDerivative · entry 2

Heerma Peter · CIK 0001789617 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,823

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001698262-26-000001 · form4-02032026_090205.xml · nonDerivative · entry 2

ROTE WILLIAM E. · CIK 0001698262 · Chief Research Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 109,087

F2 · kind: This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

SEC source: 0001283303-26-000002 · form4-02032026_090203.xml · nonDerivative · entry 2

REED ELIZABETH E · CIK 0001283303 · Chief Legal Officer and GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,205

F2 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person.

SEC source: 0001882909-26-000001 · form4-02032026_090201.xml · derivative · entry 3

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,160

Underlying: Common Stock · 20,160 shares

Expires 2036-01-31

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

SEC source: 0001882909-26-000001 · form4-02032026_090201.xml · nonDerivative · entry 1

Calvin Sandra · CIK 0001882909 · SVP, CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,413

F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

SEC source: 0001902368-26-000003 · form4-02032026_090210.xml · derivative · entry 3

Inrig Jula · CIK 0001902368 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2036-01-31

F3 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.